Natco Pharma gets EIR from USFDA

Natco Pharma Limited has received EIR from the USFDA for Kothur's formulation facility.

341
USFDA
Picture: Pixabay

Natco Pharma Limited has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for Kothur’s formulation facility.

“The inspection is conducted at its drug formulations facility in Kothur village, Telangana, India, during the period from March 2 to 6, 2020,” says Natco Pharma.

Also read: Granules India gets USFDA nod for Trospium chloride capsules

Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India, and among the country’s top three in producing hepatitis C drugs.